Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Lantheus is most often covered alongside EVERTEC, which appears in 1 of these 1 story. Source depth averages 4 original sources per story, versus 4 across the same-window beat baseline.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Lantheus is most often covered alongside EVERTEC, which appears in 1 of these 1 story. Source depth averages 4 original sources per story, versus 4 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 5.7 in the same window. Lantheus appears in 1 tracked Healthcare story from February 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 31 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Lantheus. Shared-story counts are live from our verified record — not editorial picks.
Investors are closely monitoring upcoming earnings from Natera and Lantheus as bellwethers for the precision medicine and radiopharmaceutical sectors. These reports will highlight the scaling of molecular residual disease testing and the competitive dynamics of advanced prostate cancer imaging.
Source: markets.financialcontent.com · markets.financialcontent.com
Lantheus is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
